Financière de Tubize S.A.
TUB
株式のランク
#2220
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
株価
$203.04
時価総額
$9.04B
変化（1日）
-7.47%
変化（1年）
-25.36%
国
BE
取引 Financière de Tubize S.A. (TUB)
カテゴリー
Healthcare
Financière de Tubize S.A.（TUB）の発行済株式数
June 2026 時点の発行済株式数 44.51M
Financière de Tubize S.A. の最新の財務報告および株価によると、現在の発行済株式数は 44.51M です。December 2023 の終わりには、同社は 44.51M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Financière de Tubize S.A.（TUB）の発行済株式数の履歴（2003 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 44.51M | 0.00% |
| 2024 | 44.51M | 0.00% |
| 2023 | 44.51M | 0.00% |
| 2022 | 44.51M | 0.00% |
| 2021 | 44.51M | 0.00% |
| 2020 | 44.51M | -0.11% |
| 2019 | 44.56M | 0.11% |
| 2018 | 44.51M | -0.06% |
| 2017 | 44.54M | 0.05% |
| 2016 | 44.52M | -0.08% |
| 2015 | 44.55M | -0.41% |
| 2014 | 44.74M | 0.29% |
| 2013 | 44.61M | 0.00% |
| 2012 | 44.61M | 0.00% |
| 2011 | 44.61M | 0.00% |
| 2010 | 44.61M | 0.00% |
| 2009 | 44.61M | 0.00% |
| 2008 | 44.61M | 0.00% |
| 2007 | 44.61M | 0.00% |
| 2006 | 44.61M | 0.00% |
| 2005 | 44.61M | -1.95% |
| 2004 | 45.49M | 41.99% |
| 2003 | 32.04M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 470.40% |
US
|
|
| 396.00M | 789.64% |
US
|
|
| 478.91M | 975.90% |
AU
|
|
| 62.19M | 39.70% |
NL
|
|
| - | - |
CH
|
